A number of arylpiperazinylalkylpyridazinones structurally related to the previously described lead A (5- {[4-(3-chlorophenyl)piperazin-1-yl]-propyl}-3-methyl-7-phenylisossazolo[4,5-d]pyridazin-4-(5H)-one) were synthesized and tested for their analgesic activity. Many of the tested molecules, at the dose of 20 mg kg-1 p.o., showed high antinociceptive activity, in particular, compounds 5a, 11c, 15a, 21 and 22, which were able to reduce the number of abdominal constrictions by more than 50% in writhing test. The pharmacological investigation of lead A led us to clarify the mechanism of action of this compound, showing that it carries out its analgesic action through the inhibition of reuptake of noradrenaline. The antinociception of some of the most interesting new molecules was completely prevented by pretreatment with R2-antagonist yohimbine, suggesting the involvement of R2-adrenoceptors, as with prototype A.

Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action / N.CESARI; C.BIANCALANI; C.VERGELLI; V. DAL PIAZ; A.GRAZIANO; P.BIAGINI; C.GHELARDINI; N.GALEOTTI; M.GIOVANNONI. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - ELETTRONICO. - 49:(2006), pp. 7826-7835. [10.1021/jm060743g]

Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action

VERGELLI, CLAUDIA;DAL PIAZ, VITTORIO;GHELARDINI, CARLA;GALEOTTI, NICOLETTA;GIOVANNONI, MARIA PAOLA
2006

Abstract

A number of arylpiperazinylalkylpyridazinones structurally related to the previously described lead A (5- {[4-(3-chlorophenyl)piperazin-1-yl]-propyl}-3-methyl-7-phenylisossazolo[4,5-d]pyridazin-4-(5H)-one) were synthesized and tested for their analgesic activity. Many of the tested molecules, at the dose of 20 mg kg-1 p.o., showed high antinociceptive activity, in particular, compounds 5a, 11c, 15a, 21 and 22, which were able to reduce the number of abdominal constrictions by more than 50% in writhing test. The pharmacological investigation of lead A led us to clarify the mechanism of action of this compound, showing that it carries out its analgesic action through the inhibition of reuptake of noradrenaline. The antinociception of some of the most interesting new molecules was completely prevented by pretreatment with R2-antagonist yohimbine, suggesting the involvement of R2-adrenoceptors, as with prototype A.
2006
49
7826
7835
N.CESARI; C.BIANCALANI; C.VERGELLI; V. DAL PIAZ; A.GRAZIANO; P.BIAGINI; C.GHELARDINI; N.GALEOTTI; M.GIOVANNONI
File in questo prodotto:
File Dimensione Formato  
316684 JMC 2006.pdf

Accesso chiuso

Tipologia: Altro
Licenza: DRM non definito
Dimensione 186.63 kB
Formato Adobe PDF
186.63 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/316684
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 38
social impact